Human Blood from Stem Cells
ACT-Advanced Cell Technology, Inc reported that it is possible to distinguish and mature human embryonic stem cells (HESCs) into functional oxygen carrying red blood cells under conditions suitable for scale-up.
The research at the Mayo Clinic and the University of Illinois, shows for the 1st time, the oxygen-carrying capacity of HESCs-origin the blood cells that is similar to normal transfusable RBCs (red blood cells), and that the cells respond to biochemical changes in a physiologically approach.
Robert Lanza said "Limitations in the supply of blood can have potentially life-threatening consequences for patients with massive blood loss,"
M.D., Chief Scientific Officer at ACT, and senior author of the study. "Embryonic stem cells represent a new source of cells that can be circulated and expanded indefinitely, providing a potentially infinite source of red blood cells for human therapy. We can currently generate 10 to 100 billion red blood cells from a single six well plate of the stem cells. The identification of a stem cell line with "O -" blood-type would permit the production of compatible "universal donor" blood. We also have work underway to generate reprogrammed (iPS) stem cells from individuals with universal-donor blood."
Actually, the efficient and controlled discrimination of hESCs into homogeneous RBC (Red blood cells) populations has not been achieved in earlier time. Now, this paper is going to explain for the 1st time, the generation of RBCs from hESCs with oxygen-transporting capacity, and that the functional properties of these cells are similar to those of normal erythrocytes.
Multiple stem cell lines stimulated to undertake distinction in vitro to form functional RBCs (blood like-A,B,O, and both RhD+ and RhD-)
Although an alternative sources of progenitors for transfusable RBCs have been examined, including cord blood, bone marrow and peripheral blood, these sources embody donor limited sources of RBCs. Moreover, the low prevalence of (O-) type blood in the general population further intensifies the consequences of blood shortages for emergency situations and battlefield trauma care, where the need for blood typing can enforce serious delays in initiating transfusions.
Another crucial concern of hESC is whether they can be enucleated in vitro. "We show that up to 65% of the blood cells underwent multiple maturation events that resulted in the extrusion of the nucleus," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper.
"They formed enucleated erythrocytes with a diameter of 6-8 (mu)m, which is similar to normal red blood cells. We also showed, the cells could express adult (beta)-globin and respond normally to biochemical changes."
"We believe this breakthrough could potentially facilitate numerous Americans," stated William M. Caldwell, CEO and Chairman of ACTC.
The researchers from Advanced Cell Technology (ACT) work together with the scientists from the University of Illinois at Chicago, and the Mayo Clinic, Rochester, Minnesota. The paper's other authors are Qiang Feng and Jennifer Park of ACT, Loyda Vida, Bao-Shiang Lee, and George Honig at the University of Florida, and Michael Strausbauch and Peter Wettstein at the Mayo Clinic.
http://bloodjournal.hematologylibrary.org/papbyrecent.dtl
ACT-Advanced Cell Technology, Inc reported that it is possible to distinguish and mature human embryonic stem cells (HESCs) into functional oxygen carrying red blood cells under conditions suitable for scale-up.
The research at the Mayo Clinic and the University of Illinois, shows for the 1st time, the oxygen-carrying capacity of HESCs-origin the blood cells that is similar to normal transfusable RBCs (red blood cells), and that the cells respond to biochemical changes in a physiologically approach.
Robert Lanza said "Limitations in the supply of blood can have potentially life-threatening consequences for patients with massive blood loss,"
M.D., Chief Scientific Officer at ACT, and senior author of the study. "Embryonic stem cells represent a new source of cells that can be circulated and expanded indefinitely, providing a potentially infinite source of red blood cells for human therapy. We can currently generate 10 to 100 billion red blood cells from a single six well plate of the stem cells. The identification of a stem cell line with "O -" blood-type would permit the production of compatible "universal donor" blood. We also have work underway to generate reprogrammed (iPS) stem cells from individuals with universal-donor blood."
Actually, the efficient and controlled discrimination of hESCs into homogeneous RBC (Red blood cells) populations has not been achieved in earlier time. Now, this paper is going to explain for the 1st time, the generation of RBCs from hESCs with oxygen-transporting capacity, and that the functional properties of these cells are similar to those of normal erythrocytes.
Multiple stem cell lines stimulated to undertake distinction in vitro to form functional RBCs (blood like-A,B,O, and both RhD+ and RhD-)
Although an alternative sources of progenitors for transfusable RBCs have been examined, including cord blood, bone marrow and peripheral blood, these sources embody donor limited sources of RBCs. Moreover, the low prevalence of (O-) type blood in the general population further intensifies the consequences of blood shortages for emergency situations and battlefield trauma care, where the need for blood typing can enforce serious delays in initiating transfusions.
Another crucial concern of hESC is whether they can be enucleated in vitro. "We show that up to 65% of the blood cells underwent multiple maturation events that resulted in the extrusion of the nucleus," stated Shi-Jiang Lu, Ph.D., Director of Differentiation at ACT and first author of the paper.
"They formed enucleated erythrocytes with a diameter of 6-8 (mu)m, which is similar to normal red blood cells. We also showed, the cells could express adult (beta)-globin and respond normally to biochemical changes."
"We believe this breakthrough could potentially facilitate numerous Americans," stated William M. Caldwell, CEO and Chairman of ACTC.
The researchers from Advanced Cell Technology (ACT) work together with the scientists from the University of Illinois at Chicago, and the Mayo Clinic, Rochester, Minnesota. The paper's other authors are Qiang Feng and Jennifer Park of ACT, Loyda Vida, Bao-Shiang Lee, and George Honig at the University of Florida, and Michael Strausbauch and Peter Wettstein at the Mayo Clinic.
http://bloodjournal.hematologylibrary.org/papbyrecent.dtl
0 Comments Here::
Post a Comment